Single-Pill Hypertension Therapy Remains Severely Underused Despite Proven Benefits
A decade of US data reveals persistent underuse of single-pill combination therapy for hypertension, despite its superiority for blood pressure control.
Summary
Researchers from Yale analyzed a decade of US prescribing data (2015–2025) and found that single-pill combination therapy — where two or more blood pressure medications are combined into one tablet — remains significantly underused for treating hypertension. This matters because taking multiple medications in one pill improves adherence, simplifies regimens, and leads to better blood pressure control compared to taking separate pills. Despite guideline support and strong clinical evidence, most hypertensive patients in the US are still prescribed separate pills. The findings highlight a stubborn gap between evidence and practice that may be contributing to poor cardiovascular outcomes. Addressing this underuse could represent one of the highest-yield, lowest-cost interventions available for reducing heart disease and stroke risk at a population level.
Detailed Summary
Hypertension remains the leading modifiable risk factor for cardiovascular disease globally, yet blood pressure control rates in the United States remain inadequate. One underutilized strategy with strong evidence behind it is single-pill combination (SPC) therapy — combining two or more antihypertensive agents into a single tablet to improve adherence and outcomes.
Researchers from Yale School of Medicine and the Yale New Haven Hospital Center for Outcomes Research and Evaluation conducted a longitudinal analysis of US prescribing patterns from 2015 to 2025. The study examined how frequently hypertensive patients received SPC therapy versus separate-pill regimens and whether utilization changed meaningfully over the decade.
The findings reveal persistent and substantial underuse of SPC therapy across the study period. Despite accumulating evidence favoring combination pills — including superior adherence, fewer missed doses, lower pill burden, and comparable or better blood pressure reduction — the majority of hypertensive patients in the US continued to be managed with multiple individual pills. Trends over the decade showed only modest improvement, suggesting systemic inertia in prescribing behavior.
The clinical implications are significant. Poor adherence to antihypertensive therapy is a well-documented contributor to uncontrolled hypertension, which in turn drives heart attack, stroke, kidney disease, and premature death. Transitioning eligible patients from multi-pill to single-pill regimens is a practical, scalable intervention that does not require new drugs or technologies — only a shift in prescribing habits.
Several caveats apply. This summary is based on the abstract only, as the full paper is not open access, so specific data on prescribing rates, patient demographics, and subgroup analyses are unavailable. Funding disclosures include ties to pharmaceutical companies such as Novartis and Pfizer, warranting consideration of potential bias, though the study's design appears observational rather than industry-sponsored in its primary aim.
Key Findings
- Single-pill combination therapy for hypertension remained persistently underused in the US from 2015 to 2025.
- Minimal improvement in SPC adoption occurred over the decade despite strong guideline support.
- Combining blood pressure medications into one pill improves adherence and cardiovascular outcomes.
- Widespread SPC adoption could reduce strokes, heart attacks, and kidney disease at low cost.
- A large evidence-to-practice gap persists in US hypertension management.
Methodology
This is a longitudinal observational study analyzing US hypertension prescribing data from 2015 to 2025, led by investigators at Yale School of Medicine. The study compared rates of single-pill combination therapy versus multi-pill regimens over time. Specific data sources, sample sizes, and analytical methods are not available from the abstract alone.
Study Limitations
This summary is based on the abstract only, as the full text is not open access; specific results, patient demographics, and methodology details are unavailable. Some authors have financial ties to pharmaceutical companies including Novartis and Pfizer, which should be noted when interpreting findings, though the study appears observational in nature.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.